Welcome to our dedicated page for Coya Therapeutics SEC filings (Ticker: COYA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Coya Therapeutics, Inc. filings document regulatory and financial disclosures for a clinical-stage biotechnology company developing Treg-enhancing biologics for neurodegenerative disorders. The record includes Form 8-K reports on operating results, corporate updates, clinical and regulatory disclosures for COYA 302, and study results involving low-dose IL-2 and CTLA4-Ig approaches in frontotemporal dementia.
Filings also cover material agreements and milestone payments under the company’s development and license relationship with Dr. Reddy’s Laboratories, board and executive-chairman changes, compensation and separation arrangements, and capital-structure disclosure for Coya’s Nasdaq-listed common stock. These documents provide formal disclosure of governance matters, collaboration economics, clinical-program status, and other material events.
Coya Therapeutics reported a Q1 2026 net loss of $7.2 million, similar to the prior year, as it continues developing its Treg-focused therapies. Collaboration revenue from its Dr. Reddy’s ALS partnership was $0.25 million. Research and development spending was $4.1 million, while general and administrative costs reached $3.8 million, including a one-time $1.0 million stock-option modification charge. Cash and cash equivalents rose to $50.7 million, helped by an $11.1 million January 2026 private placement, and management expects this to fund operations into the second half of 2027. As a key pipeline milestone, the FDA granted Fast Track Designation to lead ALS candidate COYA 302.
Coya Therapeutics reports first-quarter 2026 results and highlights FDA Fast Track Designation for COYA 302 in amyotrophic lateral sclerosis. Cash and cash equivalents were $50.7 million as of March 31, 2026, after a recent $11.0 million private placement.
Collaboration revenue was $0.25 million, similar to the prior-year quarter. Research and development expense fell to $4.1 million from $5.2 million, while general and administrative expense rose to $3.8 million, mainly from a $1.0 million non-cash stock option modification. Net loss was $7.2 million, roughly flat year over year.
The company advanced its COYA 302 program, including Fast Track Designation, IND acceptance for frontotemporal dementia, protocol changes to broaden Phase 2 ALS trial enrollment, and multiple planned data and trial milestones in the second half of 2026.
Coya Therapeutics, Inc. director Mark H. Pavao received a grant of stock options covering 10,000 shares of common stock. The options have an exercise price of $4.53 per share, expire on April 9, 2036, and will vest 100% on the first anniversary of the grant date, subject to continuous service.
Coya Therapeutics, Inc. filed an initial insider ownership report for director Mark H. Pavao on Form 3. This filing establishes his status as a reporting person and provides a baseline for tracking any future changes in his ownership of Coya Therapeutics securities.
Coya Therapeutics, Inc. announced a planned board transition in which founder Howard Berman, Ph.D., resigned as Executive Chairman and director effective April 1, 2026, under a Separation and General Release Agreement that provides a prorated 2026 bonus, COBRA premium coverage and extended stock option vesting and exercise periods.
The board appointed biopharmaceutical executive Mark H. Pavao as an independent Class III director, effective April 1, 2026, with a term running to the 2028 annual meeting and a grant of options to purchase 10,000 shares vesting after one year, alongside standard non‑employee director compensation.
Coya Therapeutics files a resale prospectus to register 2,522,727 shares of common stock for resale by selling stockholders. The registration covers 2,522,727 shares issued in a private placement on January 30, 2026 and states the Company will not receive any proceeds from resales.
The prospectus notes 23,457,183 shares outstanding as of March 10, 2026 and discloses a Nasdaq last sale price of $4.27 on March 19, 2026. The registration permits the selling stockholders to sell shares in various manners described under the Plan of Distribution.
Coya Therapeutics, Inc. registers for resale 2,522,727 shares of common stock issued in a January 29, 2026 private placement. The prospectus states these Shares were issued in the Private Placement at $4.40 per share and that the Company will receive no proceeds from resales by the selling stockholders.
The filing lists selling holders (including Greenlight Capital and Dr. Reddy’s), describes allowable methods of resale, and confirms the Company will pay registration expenses. Shares outstanding were 23,457,183 as of March 10, 2026.
Coya Therapeutics, Inc. is a clinical-stage biotech focused on therapies that enhance regulatory T cells to treat neurodegenerative, autoimmune and metabolic diseases. Its lead biologic, COYA 302, is in a Phase 2 ALSTARS trial for ALS after FDA IND acceptance, with an additional IND cleared for frontotemporal dementia. The company is also advancing COYA 303 and the low-dose IL-2 backbone COYA 301, plus Treg-derived exosome programs.
Coya reported a 2025 net loss of $21.2 million, up from $14.9 million in 2024, and an accumulated deficit of $62.0 million as of December 31, 2025. In January 2026 it raised $11.1 million in gross proceeds, including $10 million from strategic collaborator Dr. Reddy's, and expects its cash runway to extend into the second half of 2027. Management nonetheless states it will need substantial additional capital and highlights going-concern uncertainty if funding is not obtained.
Coya Therapeutics reported full-year 2025 results alongside a broad corporate update. Collaboration revenue rose to $7.9M from $3.6M, mainly from $6.7M of license milestones tied to its COYA 302 ALS program. Operating expenses increased to $30.5M, driven by higher clinical and R&D spending and greater general and administrative costs.
Net loss widened to $21.2M from $14.9M, reflecting heavier investment in development. Cash and cash equivalents were $46.8M at year-end. The company completed a $23.0M upsized public offering and an $11.1M private placement, extending its stated cash runway into the second half of 2027.
Coya advanced COYA 302 into the ALSTARS Phase 2 ALS trial across roughly 25 sites in the U.S. and Canada, received FDA and Health Canada clearances for new indications, and reported supportive translational and preclinical data for COYA 302 and COYA 303. Multiple clinical and publication milestones are targeted through 2026.